🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

57,13 USD

Máx. histórico

149,13

4125 días

Caída desde máximo

-61,69%

Rango 52 semanas

49,26 – 70,98

Variación hoy

+2,64%

Cierre anterior

55,66

Rango de hoy

55,67 – 57,51

Volumen hoy

2.843.464

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,04 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 2 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/08/2021 77,63 77,75 76,41 77,65 +0,31% 1,73% 793.200
02/08/2021 76,69 77,74 76,50 77,41 +0,89% 1,62% 983.200
30/07/2021 78,60 78,80 76,62 76,73 -2,27% 2,77% 909.000
29/07/2021 78,75 81,56 78,36 78,51 -0,28% 4,06% 1.136.300
28/07/2021 78,27 79,34 78,18 78,73 +0,51% 1,48% 663.700
27/07/2021 77,55 78,50 76,50 78,33 +1,27% 2,58% 927.200
26/07/2021 76,91 77,97 76,61 77,35 +0,40% 1,77% 999.800
23/07/2021 78,88 78,88 76,42 77,04 -1,81% 3,12% 1.455.400
22/07/2021 79,39 79,77 78,42 78,46 -1,49% 1,70% 616.600
21/07/2021 79,48 80,01 78,44 79,65 +0,19% 1,98% 679.900
20/07/2021 79,25 80,17 78,95 79,50 +0,93% 1,54% 1.182.800
19/07/2021 77,39 79,24 77,35 78,77 -0,09% 2,44% 1.048.400
16/07/2021 79,95 80,06 78,45 78,84 -0,92% 2,01% 855.900
15/07/2021 79,39 79,99 78,29 79,57 -0,14% 2,14% 1.381.200
14/07/2021 81,66 81,78 79,58 79,68 -2,23% 2,69% 946.200
13/07/2021 81,99 82,39 81,22 81,50 -1,01% 1,43% 495.200
12/07/2021 83,84 83,84 81,81 82,33 -1,54% 2,42% 612.600
09/07/2021 83,13 83,72 82,79 83,62 +0,81% 1,12% 609.400
08/07/2021 82,26 83,58 81,50 82,95 -0,11% 2,53% 1.021.400
07/07/2021 84,75 84,80 82,88 83,04 -1,81% 2,27% 1.193.000
06/07/2021 85,35 85,35 84,00 84,57 -1,05% 1,58% 829.000
02/07/2021 84,23 85,74 83,46 85,47 +1,86% 2,71% 947.400
01/07/2021 83,26 83,95 82,97 83,91 +0,56% 1,18% 827.800
30/06/2021 83,42 83,82 82,75 83,44 -0,02% 1,28% 770.600
29/06/2021 84,23 85,20 82,96 83,46 -1,15% 2,66% 609.000
28/06/2021 85,79 86,33 83,87 84,43 -0,42% 2,87% 534.100
25/06/2021 84,33 85,50 83,20 84,79 +1,21% 2,73% 4.825.100
24/06/2021 83,23 84,17 82,91 83,78 +1,45% 1,51% 1.081.800
23/06/2021 80,79 82,87 80,79 82,58 +1,77% 2,57% 1.256.800
22/06/2021 80,92 81,53 80,14 81,14 +0,47% 1,72% 1.202.500